| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Arcturus Therapeutics (NASDAQ:ARCT) is gearing up to announce its quarterly earnings on Monday, 2025-11-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Arcturus Therapeutics will report an earnings per share (EPS) of $-0.98.
The announcement from Arcturus Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Last quarter the company beat EPS by $0.62, which was followed by a 30.73% increase in the share price the next day.
Here's a look at Arcturus Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.96 | -1.10 | -0.49 | -1.22 |
| EPS Actual | -0.34 | -0.52 | -1.11 | -0.26 |
| Price Change % | 31.00 | 2.00 | -9.00 | 5.00 |
Shares of Arcturus Therapeutics were trading at $8.29 as of November 06. Over the last 52-week period, shares are down 59.5%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Arcturus Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ARCT
